cimetidine has been researched along with Critical Illness in 6 studies
Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.
cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.
Critical Illness: A disease or state in which death is possible or imminent.
Excerpt | Relevance | Reference |
---|---|---|
"The observed effects of cimetidine and sucralfate on the incidence and severity of hemorrhage from stress-related gastritis were not significant when compared with no treatment." | 5.07 | Prophylaxis for stress-related gastric hemorrhage in the medical intensive care unit. A randomized, controlled, single-blind study. ( Ben-Menachem, T; Bresalier, RS; Divine, G; Fogel, R; Hadzijahic, N; Patel, RV; Touchette, M; Verter, J; Zarowitz, BJ, 1994) |
"Cimetidine treatment decreased mucus/mucin content after 3 or 6 days of treatment." | 1.37 | H2 blockers decrease gut mucus production and lead to barrier dysfunction in vitro. ( Diebel, LN; Hall-Zimmerman, L; Liberati, DM, 2011) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lou, W | 1 |
Xia, Y | 1 |
Xiang, P | 1 |
Zhang, L | 1 |
Yu, X | 1 |
Lim, S | 1 |
Xu, M | 1 |
Zhao, L | 1 |
Rydholm, H | 1 |
Traxler, B | 1 |
Qin, X | 1 |
García-Rayado, G | 1 |
Lanas, A | 1 |
Tsai, JJ | 1 |
Lin, HJ | 1 |
Diebel, LN | 1 |
Liberati, DM | 1 |
Hall-Zimmerman, L | 1 |
Yang, YX | 1 |
Lewis, JD | 1 |
Ben-Menachem, T | 1 |
Fogel, R | 1 |
Patel, RV | 1 |
Touchette, M | 1 |
Zarowitz, BJ | 1 |
Hadzijahic, N | 1 |
Divine, G | 1 |
Verter, J | 1 |
Bresalier, RS | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Effect of Intravenous Esomeprazole Versus Cimetidine in Prevention of Stress Ulcer Prophylaxis in Chinese Seriously Ill Patients - a Randomized, Double-blind, Parallel-group Study[NCT02157376] | Phase 3 | 343 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
Lactobacillus GG in the Prophylaxis of Ventilator Associated Pneumonia: A Prospective, Randomized, Placebo-controlled, Double-blind Study[NCT00613795] | Phase 3 | 125 participants (Anticipated) | Interventional | 2004-08-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Criteria for a significant upper GI bleeding as described in primary outcome measure or,~Criteria for a non-significant upper GI bleeding as:~Bright red blood per NG or OG tube that clear after NG or OG tube adjustment and 5 to 10 minutes of lavage with room temperature normal saline or,~Persistent gastroccult- positive coffee ground material~During IMP treatment Day 1-2:~Persistent gastroccult - positive coffee ground material for at less than eight consecutive hours or that clear with at least 100 ml of lavage with room temperature normal saline.~During IMP treatment Day 3-14:~Persistent gastroccult - positive coffee ground material in less than three consecutive gastric aspirates within 2 to 4 hours (at least 60±20 minutes apart), or that clear with at least 100 ml of lavage with room temperature normal saline or,~Any clinical signs of hematemesis or melena or haematochezia judged (by the Investigator) to be from an upper GI source." (NCT02157376)
Timeframe: 1-14 days
Intervention | proportion of participants (Number) |
---|---|
Esomeprazole | 0.109 |
Cimetidine | 0.105 |
"Criteria for a clinically significant upper GI bleeding as:~Bright red blood per NG or OG tube that did not clear after NG or OG tube adjustment and 5 to 10 minutes of at least 100 ml lavage with room temperature normal saline-or,~Persistent gastroccult- positive coffee ground material~During IMP treatment Day 1-2:~Persistent gastroccult- positive coffee ground material for at least eight consecutive hours that did not clear with at least 100 ml of lavage with room temperature normal saline.~During IMP treatment Day 3-14:~Persistent gastroccult- positive coffee ground material in at least three consecutive gastric aspirates within 2 to 4 hours (at least 60 ±20 minutes apart), that did not clear with at least 100 ml of lavage with room temperature normal saline." (NCT02157376)
Timeframe: 1-14 days
Intervention | % of participants (Number) |
---|---|
Esomeprazole | 2.7 |
Cimetidine | 4.6 |
1 review available for cimetidine and Critical Illness
Article | Year |
---|---|
Prevention and treatment of stress ulcers in critically ill patients.
Topics: Aged; Anti-Ulcer Agents; Cimetidine; Critical Illness; Female; Gastric Mucosa; Gastrointestinal Hemo | 2003 |
2 trials available for cimetidine and Critical Illness
Article | Year |
---|---|
Prevention of upper gastrointestinal bleeding in critically ill Chinese patients: a randomized, double-blind study evaluating esomeprazole and cimetidine.
Topics: Adult; Aged; Cimetidine; Critical Illness; Double-Blind Method; Esomeprazole; Female; Gastrointestin | 2018 |
Prophylaxis for stress-related gastric hemorrhage in the medical intensive care unit. A randomized, controlled, single-blind study.
Topics: Adult; Aged; Blood Transfusion; Cimetidine; Critical Illness; Cross Infection; Female; Gastritis; Ga | 1994 |
3 other studies available for cimetidine and Critical Illness
Article | Year |
---|---|
Upper gastrointestinal bleeding in critically ill patients: proton-pump inhibitors, histamine-2 receptor antagonists or placebo? Many questions remain unanswered.
Topics: Cimetidine; Critical Illness; Double-Blind Method; Esomeprazole; Gastrointestinal Hemorrhage; Histam | 2018 |
Intermittent intravenous pantoprazole and continuous cimetidine infusion: effect on gastric pH control in critically ill patients at risk of developing stressed related mucosal disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cimetidine; Critical Illness; Gastric Mu | 2008 |
H2 blockers decrease gut mucus production and lead to barrier dysfunction in vitro.
Topics: Bacterial Adhesion; Cimetidine; Critical Illness; Escherichia coli; Histamine H2 Antagonists; HT29 C | 2011 |